Adult Brainstem Glioma Clinical Trial
— TEMOTRAD01Official title:
First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression
This phase 2 study is a prospective cohort study. Chemotherapy alone will be proposed to adult patients suffering from a "low grade" brainstem glioma subtype showing infiltrative, non-threatening clinico-radiological progression. Patients will receive temozolomide at a monthly standard dose of 150-200 mg/m2/j J1-J5, will be clinically evaluated every month and will undergo radiological evaluation every 2 months. The duration of treatment will be 12 months. Then, the patients will be followed-up until progression, with clinical evaluations and MRI performed every 2-3 months. At the time of recurrence, treatment with focal radiation therapy will be administered (54 Gy in classical fractions).
| Status | Recruiting |
| Enrollment | 60 |
| Est. completion date | September 30, 2023 |
| Est. primary completion date | April 30, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - 18 years of age or older - Karnofsky's Index over 50 - Non-contrast lesion on MRI - Histologically proven low grade brainstem glioma with 2 exceptions: - formal contraindication to surgery determined via discussion of the case with expert neurosurgeons during a national webmeeting (GLITRAD) - negative brainstem biopsy These two exceptions may lead to case-by-case inclusion despite the lack of a histologically-proven diagnosis if clinical and radiological evidence support such a diagnosis and if a very detailed systemic check-up, standardized by the GLITRAD group (spinal MRI, whole body CT, PET, LP (if feasible), blood inflammatory and infectious counts, biopsy of the salivary glands, etc) is negative and allows us to state that this diagnosis is highly probable - Clinical and/or radiological progression with an infiltrative but non-threatening pattern, warranting antitumoral treatment - Absolute neutrophil count > 1.5 x 109/l, - Platelets > 100 x 109/l - Total bilirubin < 1.5 × ULN, - AST and ALT< 3 x ULN - Effective contraception - Negative pregnancy test (serum beta-HCG) in females of reproductive age - Written informed consent - Affiliation to a social security scheme Exclusion Criteria: - Pilocytic astrocytoma - Ependymoma - Lack of a histologically proven diagnosis or an uncertain diagnosis regarding the tumoral nature and/or glial nature of the lesion after the GLITRAD webmeeting and a very detailed checkup looking for diagnostic pitfalls - Contrast enhancement on MRI - Clinico-radiological data favoring a more aggressive lesion, such as a high grade glioma, even in the case of a "low grade glioma" diagnosis after biopsy, suggesting histological under-grading - Previous radiotherapy or chemotherapy for this lesion - Contraindication to Temozolomide (Hypersensitivity to Temozolomide, dacarbazine or severe myelosuppression) - Contraindication to IRM (pacemaker, intraocular metallic foreign bodies, intracranial metal clips, non-removable hearing aids, neurostimulation electrodes ...) - Contraindication to IASOdopa® (hypersensitivity) - Severe renal insufficiency - Concomitant serious illness unbalanced that may interfere with follow-up - History of malignancy within 5 years (excluding basal cell carcinoma or in situ carcinoma of the cervix) - Pregnancy or breastfeeding - Predictable difficulty with follow-up - Patient under legal protection measures |
| Country | Name | City | State |
|---|---|---|---|
| France | APHP - Groupe Hospitalier Pitié-Salpêtrière | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Assistance Publique - Hôpitaux de Paris |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Objective response rate based on best response (Complete Response (CR) and Partial Response (PR)) to Temozolomide according to RANO criteria. | A patient will be considered to be in an objective response to Temozolomide if the best response is a complete or partial response defined according to the RANO criteria. | Baseline, every month for up to 12 months from start of treatment | |
| Secondary | Progression-free survival | 15 months or later, up to 48 months | ||
| Secondary | Histological pattern of adult brainstem gliomas | Description of the histological pattern of adult brainstem gliomas | 15 months | |
| Secondary | Molecular pattern of adult brainstem gliomas | Description of the molecular pattern of adult brainstem gliomas | 15 months | |
| Secondary | Radiological pattern of adult brainstem gliomas based on standard and multimodal MRI | Description of the radiological pattern of adult brainstem gliomas | 15 months | |
| Secondary | Metabolic pattern of adult brainstem gliomas based on 18F-DOPA PET CT at initial diagnosis and its change after treatment | Description of the metabolic pattern of adult brainstem gliomas | 15 months | |
| Secondary | Volumetric velocity of the tumor growth before treatment start from the initial MRI until the last MRI before beginning of the treatment, established with sagittal cube FLAIR sequences | Description of the volumetric growth of adult brainstem gliomas before treatment | Approximatively one month (before beginning of treatment) | |
| Secondary | Volumetric velocity of the tumor growth during treatment of chemotherapy, established with sagittal cube FLAIR sequences | Description of the volumetric growth of adult brainstem gliomas before treatment | 12 months | |
| Secondary | Volumetric velocity of the tumor growth after treatment of chemotherapy, established with sagittal cube FLAIR sequences | Description of the volumetric growth of adult brainstem gliomas after treatment | up to 48 months | |
| Secondary | Overall Survival | 15 months or later, up to 48 months | ||
| Secondary | Total score of quality of life measured by European Organization for the Research and Treatment of Cancer Quality of Life questionnaires(EORTC QLQ-C30 and EORTC QLQ-BN20 together) during treatment | Every 2 months up to 12 months | ||
| Secondary | 15-month life quality as measured by total score of European Organization for the Research and Treatment of Cancer Quality of Life questionnaires(EORTC QLQ-C30 and EORTC QLQ-BN20 together) | At 15 months | ||
| Secondary | Objective response rate based on best response (CR and PR) to Temozolomide according to RANO criteria combined with total score obtained on three scales (ataxia measured by the SARA scale, diet/swallowing measured by the FOIS scale and diplopia). | A patient will be considered to be in an objective response to Temozolomide if the best response is a complete or partial response defined according to the RANO criteria and without degradation on the three scales or if the best response is stable according to RANO criteria with an improvement on one on the three scales without degradation of the two others.
An improvement is defined as an improvement of total score obtained on one of the three scales without degradation of the two others. Stabilization is defined as obtaining the same total score on all three scales. Degradation is defined as degradation of total score on at least one of the scales (even if the score obtained on another scale is improved) |
Baseline, every month for up to 12 months from start of treatment | |
| Secondary | Tolerance to Temozolomide defined by the frequencies and grades of adverse events defined by the CTCAE v5.0 November 27, 2017 | During chemotherapy and until 12 months |